Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theo de Witte

Showing results (101-110 of 151) with videos related to

Pageof 16
Sort By:
Annals of Hematology|September 25, 2015
Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG)Heiko Becker, Stefan Suciu, Björn Hans Rüter, et al.
Haematologica|December 8, 2018
Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotypeFrédéric Baron, Marian Stevens-Kroef, Michal Kicinski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study GroupMichael Lübbert, Stefan Suciu, Liliana Baila, et al.
The Journal of Clinical Investigation|November 13, 2013
Induction of myelodysplasia by myeloid-derived suppressor cellsXianghong Chen, Erika A Eksioglu, Junmin Zhou, et al.
Blood|March 14, 2013
Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 studyGösta Gahrton, Simona Iacobelli, Bo Björkstrand, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 25, 2019
Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow TransplantationMartin Carré, Raphaël Porcher, Jürgen Finke, et al.
Annals of Hematology|June 22, 2018
Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trialsFrédéric Baron, Marian Stevens-Kroef, Michal Kicinski, et al.
British Journal of Haematology|May 21, 2024
Inflammatory profile of lower risk myelodysplastic syndromesJoanne Topping, Adele Taylor, Fatima Nadat, et al.
British Journal of Haematology|November 6, 2022
Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registryKrzysztof Mądry, Karol Lis, Pierre Fenaux, et al.
Bone Marrow Transplantation|February 27, 2022
Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMTEdouard Forcade, Sylvie Chevret, Jürgen Finke, et al.
Pageof 16

Showing results (101-110 of 151) with videos related to

Sort By:
Pageof 16
Annals of Hematology|September 25, 2015
Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG)Heiko Becker, Stefan Suciu, Björn Hans Rüter, et al.
Haematologica|December 8, 2018
Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotypeFrédéric Baron, Marian Stevens-Kroef, Michal Kicinski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study GroupMichael Lübbert, Stefan Suciu, Liliana Baila, et al.
The Journal of Clinical Investigation|November 13, 2013
Induction of myelodysplasia by myeloid-derived suppressor cellsXianghong Chen, Erika A Eksioglu, Junmin Zhou, et al.
Blood|March 14, 2013
Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 studyGösta Gahrton, Simona Iacobelli, Bo Björkstrand, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 25, 2019
Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow TransplantationMartin Carré, Raphaël Porcher, Jürgen Finke, et al.
Annals of Hematology|June 22, 2018
Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trialsFrédéric Baron, Marian Stevens-Kroef, Michal Kicinski, et al.
British Journal of Haematology|May 21, 2024
Inflammatory profile of lower risk myelodysplastic syndromesJoanne Topping, Adele Taylor, Fatima Nadat, et al.
British Journal of Haematology|November 6, 2022
Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registryKrzysztof Mądry, Karol Lis, Pierre Fenaux, et al.
Bone Marrow Transplantation|February 27, 2022
Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMTEdouard Forcade, Sylvie Chevret, Jürgen Finke, et al.
Pageof 16